G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 253-264

  Nakamura, Atsushi ^a,b   Fujita, Masahide ^a   Ono, Hiroko ^a   Hongo, Yoshie ^a   Kanbara, Tomoe ^a,b   Ogawa, Koichi ^a   Morioka, Yasuhide ^a   Nishiyori, Atsushi ^a   Shibasaki, Masahiro ^b   Mori, Tomohisa ^b   Suzuki, Tsutomu ^b   Sakaguchi, Gaku ^a   Kato, Akira ^a   Hasegawa, Minoru ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

opioid receptor; antinociception; G protein gated inwardly rectifying potassium channel; morphine; oxycodone

Indexed keywords

FENTANYL CITRATE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; MORPHINE; OPIATE; OXYCODONE; POTASSIUM CHANNEL BLOCKING AGENT; SMALL INTERFERING RNA; TERTIAPIN Q; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BONE CANCER; CANCER PAIN; CHRONIC PAIN; CONTROLLED STUDY; FEMALE; FEMUR TUMOR; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TREATMENT RESPONSE;

ANTINOCICEPTION; G PROTEIN-GATED INWARDLY RECTIFYING POTASSIUM CHANNEL; MORPHINE; OXYCODONE; Μ-OPIOID RECEPTOR;

ANIMALS; BRAIN; CHRONIC PAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MORPHINE; NARCOTICS; NEURALGIA; NOCICEPTION; OXYCODONE; PAIN MEASUREMENT; POTASSIUM CHANNEL BLOCKERS; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOPUS LAEVIS;

EID: 84890283022     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12441     Document Type: Article

References (37)

1. Alexander SPH, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Bercovitch M, Adunsky A, (2006). High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20: 33-39.
3. Bostrom E, Simonsson US, Hammarlund-Udenase M, (2006). In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos 34: 1624-1631.
4. Bostrom E, Hammarlund-Udenase M, Simonsson US, (2008). Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 108: 495-505.
5. Chang SC, Lutfy K, Sierra V, Yoburn BC, (1991). Dissociation of opioid receptor upregulation and functional supersensitivity. Pharmacol Biochem Behav 38: 853-859.
6. Cruz HG, Berton F, Sollini M, Blanchet C, Pravetoni M, Wickman K, et al. (2008). Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. J Neurosci 9: 4069-4077.
7. Heiskanen T, Kalso E, (1997). Controlled-release oxycodone and morphine in cancer related pain. Pain 73: 37-45.
8. Hoehn K, Reid A, Sawynok J, (1988). Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, noradrenaline and baclofen. Eur J Pharmacol 27: 65-72.
9. Honore P, Lugar NM, Sabino MAC, Schwei MJ, Rogers SD, Mash DB, et al. (2000). Osteroprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-induced neurochemical reorganization of the spinal cord. Nat Med 6: 521-528.
10. Ikeda K, Kobayashi T, Kumanishi T, Niki H, Yano R, (2000). Involvement of G-protein-activated rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci Res 38: 113-116.
11. Jin W, Lu Z, (1998). A novel high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry 37: 13291-13299.
12. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
13. Klimas R, Witticke D, El Fallsh S, Mikus G, (2013). Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration. Expert Opin Drug Metab Toxicol 9: 517-528.
14. Komiya S, Zenmyo M, Inoue A, (1999). Bone tumors in the pelvis presenting growth during pregnancy. Arch Orthop Trauma Surg 119: 22-29.
15. Koyyalagunta D, Bruera E, Solanki DR, Nouri KH, Burton AW, Toro MP, et al. (2012). A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 15: ES39-ES58.
16. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, et al. (2006). Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 105: 801-812.
17. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
18. Malmberg AB, Basbaum AI, (1998). Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain 76: 215-222.
19. Marker CL, Cintora SC, Roman MI, Stoffel M, Wickman K, (2002). Hyperalgesia and blunted morphine analgesia in G protein-gated potassium channel subunit knockout mice. Neuroreport 20: 2509-2513.
20. Marker CL, Stoffel M, Wickman K, (2004). Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J Neurosci 17: 2806-2812.
21. Mercadante S, Arcuri E, (1998). Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425-432.
22. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al. (2009). Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111: 60-72.
23. Mitrovic I, Margeta-Mitrovic M, Bader S, Stoffel M, Jan LY, Basbaum AI, (2003). Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha2-adrenergic analgesia and analgesic sex differences. Proc Nalt Acad Sci USA 100: 271-276.
24. Moulin DE, Iezzi A, Ameireh R, Sharpe WKJ, Boyd D, Merskey H, (1996). Randomised trial of oral morphine for chronic non-cancer pain. Lancet 347: 143-147.
25. Nakamura A, Hasegawa M, Minami K, Kanbara T, Tomii T, Nishiyori A, et al. (2013). Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol 168: 375-388.
26. Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, et al. (2008). Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 33: 1097-1112.
27. Pandit-Taskar N, Batraki M, Divgi CR, (2004). Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45: 1358-1365.
28. Peckham EM, Traynor JR, (2006). Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316: 1195-1201.
29. Portenoy RK, Payne D, Jacobsen P, (1999). Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81: 129-134.
30. Seltzer D, Dubner R, Shir Y, (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
31. Shah S, Breivogel C, Selly D, Munirathinam G, Childers S, Yoburn BC, (1997). Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice. Pharmacol Biochem Behav 56: 465-469.
32. Silvestri B, Bandieri E, Del Prete S, Ianniello GP, Micheletto G, Dambrosio M, et al. (2008). Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. Clin Drug Investig 28: 399-407.
33. Tunblad K, Jonsson EN, Hammarlund-Udenaes M, (2003). Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res 20: 618-623.
34. Vaughan CW, Ingram SL, Connor MA, Christie MJ, (1997). How opioids inhibit GABA-mediated neurotransmission. Nature 390: 611-614.
35. Watson CP, Babul N, (1998). Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50: 1837-1841.
36. Yoshimura M, North RA, (1983). Substantia gelatinosa neurons hyperpolarized in vitro by encephalin. Nature 305: 529-530.
37. Yow TT, Pera E, Absalom N, Heblinski M, Johnston GA, Hanrahan JR, et al. (2011). Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q. Br J Pharmacol 163: 1017-1033.